Skip to main content

Advertisement

Table 3 Multivariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS

From: Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

  PFS OS
HR [95% CI] P HR [95% CI] P
Age >60 years 2.40 [0.90, 6.38] 0.08 1.75 [0.37, 8.24] 0.48
Ann Arbor stage IIIE-IVE 5.65 [1.47, 21.80] 0.01 9.55 [0.87, 104.27] 0.06
LDH above normal 2.16 [0.72, 6.48] 0.17 3.60 [0.56, 23.12] 0.18
ECOG >1 2.80 [0.93, 8.48] 0.07 3.93 [0.78, 20.02] 0.10
No. of extranodal sites >3 5.34 [1.40, 20.32] 0.01 6.81 [1.09, 42.72] 0.04
hypercalcemia 1.76 [0.36, 8.54] 0.48 6.92 [1.09, 44.01] 0.04
AP above normal 0.93 [0.29, 2.97] 0.90 0.67 [0.13, 3.38] 0.63
Multifocal bone lesions 0.35 [0.11, 1.11] 0.08 0.39 [0.08, 1.81] 0.23
Rituximab 0.16 [0.04, 0.62] 0.008 0.23 [0.03, 1.80] 0.16
Intensified chemotherapy 0.50 [0.17, 1.49] 0.21 0.62 [0.13, 2.96] 0.55
Radiotherapy 0.13 [0.04, 0.42] 0.0006 0.01 [0.0006, 0.18] 0.002
  1. Abbreviations: HR indicates hazard ratio, CI confidence interval, and P p-value